PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients

FERRARI, LUCIANA C; RIVAS, MARÍA M; NAVICKAS, ALICIA B; DICK, HERNÁN; MELA OSORIO, MARÍA J; AGAMENNONI, LUCÍA; REY, IRENE H; CARNELUTTO, NATALIA E; CAZAP, NICOLÁS; CASTRO, MARÍA B; ARANGUREN, PEDRO NEGRI; FISCHMAN, LAURA A; YUPANKI, MARCO LINCANGO; MILONE, JORGE H; FERNÁNDEZ, ISOLDA I; MOIRANO, MARÍA M; BELLI, CAROLINA B

ANNALS OF HEMATOLOGY

SPRINGER

Lugar: Berlin; Año: 2023 vol. 102 p. 1087 - 1907

0939-5555

Intensified pediatric chemotherapy regimens to treat adolescents and young adults (AYA) patients with Philadelphia negative acute lymphoblastic leukemia (ALL) have been associated with better outcomes. The local BFM 2009-based scheme complements the risk stratification assessing the measurable residual disease (MRD) along the induction phase with increasing levels of sensitivity. The present retrospective multicenter analysis included 171 AYA (15–40 years) patients treated accordingly between 2013 and 2019. Ninety-one percent obtained morphological complete remission, 67% a negative (